1. Introduction
===============

Over the years, there has been an important number of attempts to classify allergic diseases, especially on respiratory level. Respiratory allergies may begin at any level of the respiratory tract (nose, sinuses, lungs) and, over time, they can generalize throughout, process known as the United Airway Disease (UAD) ([@b1-etm-0-0-8961]). One of them was based on the evaluation of specific mechanisms that represent the pathophysiological background of the disease: endotypes ([@b2-etm-0-0-8961]). A disease endotype includes the specific biological pathway (describing an etiology and/or a firm pathophysiologic mechanism) that explains the observable properties of a phenotype (clinical description of a disease without a connection with underlying pathology). Lötvall *et al* ([@b2-etm-0-0-8961]) were the first to propose the criteria that characterizes an endotype. In order to be accepted, an endotype description should take into account at least 5 of these 7 aspects: Clinical, biomarkers, lung function, genetics, histopathology, epidemiology and treatment response ([@b3-etm-0-0-8961]). At the moment, there are two main endotypes described: Th2 and non-Th2.

2. Th2 endotype
===============

Over the last decade, one of the most studied endotypes was the one based on type 2 immune response. Historically, allergic asthma and rhinitis were hypothesized to be produced by this type of mechanism ([@b4-etm-0-0-8961],[@b5-etm-0-0-8961]). Type 2 immune response is based on the contribution of the following cells: Th2 cells ([@b6-etm-0-0-8961]), type 2 B cells ([@b7-etm-0-0-8961]), interleukin-4 (IL-4) secreting NK cells ([@b8-etm-0-0-8961]), IL-4 secreting T-NK cells ([@b9-etm-0-0-8961]), mast cells, eosinophils, basophils, their cytokines (CK) ([@b5-etm-0-0-8961]): IL-4, IL-5, IL-9, IL-13, along with those CKs secreted by tissue cells ([@b5-etm-0-0-8961]): IL-25([@b10-etm-0-0-8961]), IL-31([@b11-etm-0-0-8961]), IL-33([@b12-etm-0-0-8961]) and TSLP ([@b13-etm-0-0-8961]). Starting from the characterization of Th2 endotype, experts identified two endotypes: Th2-high and Th2-low ([@b14-etm-0-0-8961]), which were divided further in several sub-endotypes: IL-5-high, IL-13-high, IgE-high ([@b5-etm-0-0-8961]). This kind of endotype may also be characterized by several other biomarkers: blood or sputum eosinophilia ([@b15-etm-0-0-8961]), periostin ([@b16-etm-0-0-8961]), considered to be characteristic for it. Type 2 immune response underlines atopic asthma and allergic rhinitis (AR) as fundamental for the united airway concept ([@b5-etm-0-0-8961]). In addition, type 2 immune response seems to be important in chronic rhinosinusitis (CRS) with nasal polyposis (CRSwNP), tissue eosinophilia and evidence of eosinophil activation, being closely associated with remodeling features of CRS ([@b5-etm-0-0-8961]). The whole disease spectrum of atopic dermatitis (AD) from background inflammation in asymptomatic patients to chronic disease is also covered by this type of mechanism ([@b5-etm-0-0-8961]).

3. Non-Th2 endotype
===================

Recent years brought to the allergist\'s attention a new endotype in allergic respiratory diseases: non-type 2 immune response driven endotype. This endotype is related to neutrophilic inflammation, Th17 activation ([@b17-etm-0-0-8961]), neurogenic inflammation and tissue remodeling ([@b4-etm-0-0-8961]). There are two major mechanisms that are considered to contribute to definition of this endotype: the activation of the IL-17-dependent pathway and neutrophil intrinsic abnormalities ([@b4-etm-0-0-8961]). It was demonstrated that IL-17 is linked to remodeling ([@b18-etm-0-0-8961]), airway hyper-reactivity (AHR) ([@b19-etm-0-0-8961]), asthma severity ([@b20-etm-0-0-8961]) and inflammation ([@b21-etm-0-0-8961]). Lung airway neutrophilia seems to be associated with lower lung function, thickening airway walls and more air trapping ([@b3-etm-0-0-8961]). For decades, Th1 immune response was considered the main mechanism responsible for the pathophysiology of non-atopic asthma ([@b5-etm-0-0-8961]). This response is characterized by the domination of Th1 cells and their mediators: interferon-γ (IFN-γ) ([@b22-etm-0-0-8961]) and tumor necrosis factor-α (TNF-α) ([@b23-etm-0-0-8961]). Initially described in non-atopic asthma or in severe asthma, it has recently been connected with allergic rhinitis and asthma as well ([@b24-etm-0-0-8961],[@b25-etm-0-0-8961]). TNF-α produces a nasal inflammatory response in patients with AR characterized by plasma exudation and late phase neutrophil activity 24 h post nasal challenge ([@b24-etm-0-0-8961]). An increase of IFN-γ levels was observed due to increased exposure to polycyclic aromatic hydrocarbons (PAHs), known for their predisposition to atopy ([@b25-etm-0-0-8961]). In recent years, mixed endotypes/sub-endotypes, such as Th1/Th17([@b4-etm-0-0-8961]) or Th2/Th17 endotype were proposed ([@b26-etm-0-0-8961]).

4. Lymphocyte diversity, plasticity and heterogeneity
=====================================================

Besides the classic difference Th1 vs. Th2, immunology has been described previously in many other types of lymphocytes. The importance of Th17 in respiratory allergies has been presented before. Th9 cells have an important role in the immune responses regulation. They express predominantly IL-9. IL-9 causes the induction of lung eosinophilia, increased serum total IgE levels, airway hyperreactivity ([@b27-etm-0-0-8961]), the generation of cytokines from active mast cells; it also up-regulates high-affinity IgE receptors on mast cells ([@b28-etm-0-0-8961]). Th22 cells are positive for chemokine receptors CCR4, CCR6 and CCR10 and produce mostly IL-22. IL-22 has been found to be increased in patients with AR ([@b29-etm-0-0-8961]) and asthma ([@b30-etm-0-0-8961]). GM-CSF producing T cells were also described. Increased levels of GM-CSF were found during the birch-pollen season in the nasal lavage ([@b31-etm-0-0-8961]). T follicular helper cells (T~FH~) represent a specialized CXCR5-expressing CD4^+^ T cell population, regulated by Bcl-6. Peripheral circulating T~FH~ can be divided into three subsets: cT~FH~ cells (BCL6^-^CXCR3^+^CCR6^-^), cT~FH2~ cells (BCL6^-^CXCR3^-^CCR6^-^), and cT~FH17~ (BCL6^-^CXCR3^-^CCR6^+^) cells, based on the differential expression of the chemokine receptors CXCR3 and CCL6([@b32-etm-0-0-8961]). Significant levels were found in child and adult asthma patients ([@b33-etm-0-0-8961]). In addition, T~FH~ were positively correlated with total IgE levels in the blood ([@b34-etm-0-0-8961]). Unconventional T lymphocytes, such as invariant natural killer T (iNKT) and mucosal-associated invariant T cells (MAIT), are considered potential candidates for studying the mechanisms underlying the pathophysiology of asthma ([@b35-etm-0-0-8961]). MAIT cells produce low-to-moderate levels of IL-4 and IL-13([@b36-etm-0-0-8961]). A recent study suggests that MAIT-17 cells may be associated with asthma symptoms ([@b37-etm-0-0-8961]).

Another important aspect is represented by the plasticity of T cells. Previously it was shown that T lymphocytes can display an important grade of plasticity when they are exposed to re-polarizing signals ([@b38-etm-0-0-8961]). Signaling via Toll-like receptors can drive Th2 cells to an IFN-γ-secreting phenotype ([@b39-etm-0-0-8961]). Th9 cells may develop from Th2 cells under the action of TGF-β ([@b40-etm-0-0-8961]). Th1/Th2 hybrid cells may develop from Th2 precursor cells under the influence of interferons ([@b41-etm-0-0-8961]). Th1 and Th17 cells may produce IL-4 under some circumstances ([@b42-etm-0-0-8961]).

5. Chemokines
=============

Chemokines (CC) are chemoattractant cytokines that signal through seven-transmembrane-spanning domain, pertussis toxin-sensitive, G-protein-coupled receptors (GPCRs). They are classified into four families, based on the arrangement of the first two N-terminal cysteine residues within their amino acid sequence: CXC(α) family, CC(β) family, CX3C(δ) family and C(γ) family. Chemokines can be divided functionally into inflammatory and homeostatic. Inflammatory chemokines are produced during an inflammatory response by activated leukocytes or tissue resident cells. Examples include CXCL9 \[monokine induced by γ-interferon (MIG)\], CXCL10 \[interferon-γ-induced protein 10 (IP-10)\] and CXCL11 (interferon-inducible T cell α-chemoattractant (ITAC)\] that attract Th1 cells and neutrophil-attracting chemokines: CXCL1 \[growth-regulated oncogene (GROα)\] and CXCL8 (interleukin-8). Homeostatic chemokines are produced by healthy tissues and direct leukocytes to fulfill their normal roles, which are immune surveillance, hematopoiesis and embryogenesis: CCL19 \[EBI1 ligand chemokine (ELC)\], CCL21 \[secondary lymphoid-tissue chemokine (SLC)\], CCL25 \[thymus-expressed chemokine (TECK)\] and CCL27 \[cutaneous T cell-attracting chemokine (CTAK)\] ([@b43-etm-0-0-8961]).

The interrelations between CC and T cells are well established ([@b43-etm-0-0-8961]). The interaction between CC, mediated by their receptors, and T cells is well documented, as well as this influence on the inflammatory infiltrate from allergic pathogenesis ([@b43-etm-0-0-8961]). Further, we will focus on the presentation of the interaction between the different subtypes of T cells and the CC regarding their contribution to the pathogenesis of respiratory allergies ([Fig. 1](#f1-etm-0-0-8961){ref-type="fig"}).

### Chemokines associated with Th2 lymphocyte function.

Th2 cells are classically associated with the CC (β) family (best studied until now are CCL1, CCL17, CCL18, CCL22) ([@b43-etm-0-0-8961]). They possess three receptors for CC: CCR3, CCR4, and CCR8. *CCL1* (also known as I-309) is a potent attractant for Th2 lymphocytes ([@b44-etm-0-0-8961]). *CCL1* represents the predominant CC secreted from IgE-activated mast cells and is found in high concentrations in asthmatic airways ([@b45-etm-0-0-8961]). Mast cells release of CCL1 was proposed to be the key step for early Th2 recruitment through the CCR8 receptor ([@b46-etm-0-0-8961]). *CCL1* was found to be significantly elevated in the bronchoalveolar fluid (BALF) from atopic asthmatic patients as compared with volunteers ([@b44-etm-0-0-8961]), and asthmatic vs. controls ([@b47-etm-0-0-8961]). The role of CCL1 in the pathogenesis of asthma was indirectly demonstrated by the suppression of its serum levels after treating human monocytic leukemia cell line THP-1 and human monocytes from healthy donors with a cysteinyl leukotriene receptor antagonist (montelukast) ([@b48-etm-0-0-8961]). Murine studies reinforced the role of CCL1 released by mast cells and basophils and its receptor (CCR8) in recruitment of IL-4, IL-5 and IL-13-secreting T lymphocytes into the airways ([@b45-etm-0-0-8961],[@b49-etm-0-0-8961]).

*CCL17* \[thymus and activation regulated chemokine (TARC)\] facilitates recruitment, activation and development of Th2-polarized cells that express CCR4([@b50-etm-0-0-8961]). CCL17 has been associated with an important role in the development of pulmonary diseases ([@b51-etm-0-0-8961]). Clinical studies that included patients with asthma demonstrated over-expression of CCL17 RNAm^+^ in patients with asthma compared with controls and a weak, but significant association with sputum eosinophilia ([@b52-etm-0-0-8961]); RNAm^+^ TARC/CCL17 cells were found elevated in the epithelium and submucosa of the bronchial biopsies of the asthmatics compared with the controls ([@b53-etm-0-0-8961]). CCL17 was also highly expressed in patients with AR or rhino-sinusitis in serum and nasal secretions compared with controls ([@b54-etm-0-0-8961]) and significantly decreased after immunotherapy in patients with dust mite allergy ([@b50-etm-0-0-8961]), suggesting an implication in nasosinusal allergy.

CCL18 \[pulmonary and activation-regulated chemokine (PARC)\] is another chemokine, production of which, is induced by the inflammatory Th2 cytokines. CCL18 exhibits dual functions, with pro- and anti-inflammatory properties, according to the environment (baseline or inflammatory) and to the genetic background. CCL18 recruits basophils and Th2 cells activates basophils and induces histamine release ([@b58-etm-0-0-8961]). CCL18 levels were found to be elevated in patients with asthma after segmental allergen challenge ([@b59-etm-0-0-8961]) and significantly correlated with sputum eosinophil percentages ([@b60-etm-0-0-8961]) in patients with dust mites allergy ([@b61-etm-0-0-8961]) and AR ([@b62-etm-0-0-8961]), results congruent with theoretical data.

CCL22 \[monocyte-derived chemokine (MDC)\] induces the selective migration of Th2 cells (roles in homing and recruitment of CC chemokine receptor 4-bearing Th2 cells in allergen-induced inflammation). High levels of CCL22 were found in the serum of patients with allergic rhinitis with sensitization to birch pollen ([@b63-etm-0-0-8961]) and ragweed pollen ([@b56-etm-0-0-8961]), which suggest a possible role in the pathogenesis of AR.

The Eotaxin family, which include Eotaxin-1 (CCL11), Eotaxin-2 (CCL24) and Eotaxin-3 (CCL26), recruits and activates CCR3-bearing cells, such as Th2 lymphocytes, mast cells and eosinophils that play an important role in allergic diseases ([@b64-etm-0-0-8961]). Eotaxin-1 was also shown to contribute in producing AHR. Eotaxin-1 presented elevated levels and good correlations with sputum eosinophilia in children with stable asthma compared with controls ([@b65-etm-0-0-8961]), and significant differences between children with asthma vs. healthy children in BAL fluid ([@b66-etm-0-0-8961]), which suggests that eotaxin-1 may regulate eosinophil trafficking into the airways of asthmatic children in a coordinated manner. High levels of eotaxin-1 were obtained after nasal allergen challenge in patients with AR comparing with controls ([@b67-etm-0-0-8961]) and in the material from nasal brushing in patients with asthma, allergic rhinitis and COPD ([@b68-etm-0-0-8961]). Eotaxin-1 was involved in acute allergic airway response to *Aspergillus fumigatus* ([@b69-etm-0-0-8961]), eosinophilic inflammation in asthma ([@b70-etm-0-0-8961]) and progress to AHR ([@b71-etm-0-0-8961]). Based on a review that included 30 studies, Eotaxin-1 was considered as a potentially useful biomarker for the diagnosis and assessment of asthma severity and control ([@b72-etm-0-0-8961]). Eotaxin-2, found in high levels in patients with nasal polyposis and perennial allergic rhinitis when comparing to controls, contribute to eosinophil attraction at the site of inflammation ([@b73-etm-0-0-8961]). Eotaxin-3 was expressed by nasal nerves of patients with AR after allergen challenge ([@b74-etm-0-0-8961]) and predisposed to AR in a Korean population ([@b75-etm-0-0-8961]).

Besides this known relationship between Th2 lymphocytes and presented chemokines, a number of studies pointed out the association of other CC and Th2 cells in the pathogenesis of respiratory allergic diseases. For instance, in the last decades, numerous studies focused on the investigation on CCL2 \[monocyte chemoattractant protein-1 (MCP-1)\], CCL5 (RANTES-regulated on activation, normal T cell expressed and secreted), CCL7 \[monocyte-chemotactic protein-3 (MCP-3)\], CCL13 \[monocyte-chemotactic protein-4 (MCP-4)\] and CX3CL1 (Fraktaline) regarding their association with inflammation in asthma and AR.

*CCL2* was found to be related to the development of airway smooth muscle (ASM) hyperplasia in asthma ([@b76-etm-0-0-8961]) and has been proven to be a good biomarker of asthma control in adults and children when it is measured in saliva along with CCL5 (RANTES) ([@b77-etm-0-0-8961]). CCL2 (MCP-1) was observed in high serum levels in experimental murine studies of allergic asthma ([@b70-etm-0-0-8961],[@b78-etm-0-0-8961]) and in bronchoalveolar lavage (BAL) from a Cynomolgus monkey model ([@b79-etm-0-0-8961]). Genetic studies proved the association between *CCL7* and asthma: -1382T/C was associated with the susceptibility to atopic asthma in an Indian population ([@b80-etm-0-0-8961]). *CCL7* was associated to the deficiency of IL17-A and suppression of eosinophil infiltration in an animal model of AR ([@b81-etm-0-0-8961]). *CCL5* (*RANTES*) was significantly higher in patients with atopic asthma than controls and positive correlated with absolute eosinophil counts and total serum IgE ([@b82-etm-0-0-8961]) in pediatric patients with asthma after exercise challenge ([@b83-etm-0-0-8961]), which seems to be associated with allergic inflammation. On the other hand, the levels of *CCL5* presented significant differences between patients with allergic and non-allergic rhinopathies and polyps vs. those with normal mucosa ([@b84-etm-0-0-8961]), which suggest its contribution to leukocyte infiltration and activation related to inflammation. Two CCL5\'SNPs (located at -403G/A and -28C/G) were evaluated and associated with the risk of asthma in Asian and Caucasian populations ([@b85-etm-0-0-8961]). *CCL13* (*MCP-4*), a CC able to induce crucial immuno-modulatory responses through its effects on epithelial, muscular and endothelial cells was also measured in studies investigating asthma and rhinitis. Significant higher plasma levels of CCL13 were found in patients with stable-asthma than in controls and those with acute asthma vs. those with stable asthma ([@b86-etm-0-0-8961]). It was shown that the CCL13 expression was stimulated by IL-4, a cytokine characteristic for Th2, in an experimental study that used airway smooth muscle cells ([@b87-etm-0-0-8961]). Moreover, serum levels of CCL13 were observed to be higher in patients with allergic rhinitis after nasal allergen challenge between patients and controls and during natural pollen exposure ([@b88-etm-0-0-8961]).

CX3CL1 (Fraktaline) has been found to be increased in allergic diseases by promoting Th2 cell survival in the inflamed airways (particularly in asthma). CX3CL1 levels were increased after segmental allergen challenge in allergic asthmatic patients ([@b89-etm-0-0-8961],[@b90-etm-0-0-8961]). The CX3CL1/CX3CR1 axis was also demonstrated to contribute to the development of allergic asthma in murine studies ([@b91-etm-0-0-8961]).

### Chemokines associated with function of Th1 lymphocytes

Th1 lymphocytes are associated with CXC chemokines, especially CXCL9, 10 and 11. Th1 lymphocytes possess the receptors CCR1, CCR5, CXCR3 and CXCR6([@b43-etm-0-0-8961]). Three CC-CXCL9 (MIG), CXCL10 (IP-10) and CXCL11 (ITAC) are described, which form a mini-cluster along the chromosome 4 at q21.21. They are inducible by IFN-γ and act on immune cells expressing CXCR3. Th1 cells express CXCR3 and thus will be attracted by these chemokines ([@b92-etm-0-0-8961]). CXCL9 and CXCL10 were released in large amounts by eosinophils obtained from the peripheral blood of allergic volunteers when these were stimulated concomitantly with TNF-α and IFN-γ ([@b93-etm-0-0-8961]). Also, it was observed that high concentrations of CXCL9, 10 and 11 were significantly elevated ([@b94-etm-0-0-8961]) in BALF after broncho-provocation with antigen in patients with asthma. Allergen activation in asthma patients provoked a diminished production of CXCL9 and CXCL10, which contributed to a skewed Th2 profile ([@b95-etm-0-0-8961]). Elevated levels of CXCL9 and CXCL10 were observed in a pediatric study in patients with an acute exacerbation in contrast to patients with stable asthma ([@b96-etm-0-0-8961]). CXCL10 proved to be a useful inflammatory marker of occupational asthma (OA) exacerbation in patients with wood dust OA in contrast with healthy controls ([@b97-etm-0-0-8961]) and in the exacerbation of childhood asthma ([@b96-etm-0-0-8961]). CXCL10 presented significant differences in patients with AR when it was measured in nasal lavage before and after allergen exposure ([@b98-etm-0-0-8961]). The development of respiratory allergies was related to decreased levels of CXCL10, particularly in patients with asthma, because this situation indirectly favors Th2 cytokines production ([@b99-etm-0-0-8961]).

### Chemokines associated with function of Th17 lymphocytes

Th17 lymphocytes were found to be associated with chemokines from the CXC family: CXCL1 (GROα), CXCL2 (GROβ), CXCL3 (GROγ), CXCL5 \[epithelial-derived neutrophil-activating peptide 78 (ENA-78)\], CXCL6 \[granulocyte chemotactic protein 2 (GCP2)\] and CXCL8 (IL-8) ([@b43-etm-0-0-8961]). These chemokines, along with CXCL7, belong to the family of ELR+CXC chemokines (characterized by the highly conserved N-terminal ELR (glutamic acid-leucine-arginine) triad and agonists for the CXCR2 receptor. Their primary role is to attract and activate neutrophils ([@b102-etm-0-0-8961]). Besides these well-known properties, a small number of studies associated these chemokines with allergic inflammation. An important body of evidence related to the contribution of these chemokines regarding allergic inflammation in respiratory diseases was obtained through experimental animal murine models. Thus, it was observed that CXCL1, a chemokine expressed on macrophages, neutrophils and epithelial cells known for its role in angiogenesis, arteriogenesis, inflammation, wound healing, and tumorigenesis had an increased expression in mouse lung epithelial cells in sensitized animals with Anisakis, which suggest that allergens can induce airway inflammation by elevating Th2 and Th17 responses ([@b103-etm-0-0-8961]). In addition, it was found that its concentration was increased in the BAL of cockroach-sensitized mice where the allergen was administered intranasally during a period of 5 days, which shows that CXCL1 might have roles in the remodeling during asthma ([@b71-etm-0-0-8961]). The expression of CXCL1 was decreased in a murine model of AR when the experimental animals were treated with flagellin-ovalbumin mixture (used as an adjuvant for immunomodulation) ([@b104-etm-0-0-8961]) and in a murine model of allergic severe asthma sensitization with house dust mites (HDM) when the researchers blocked the activity of IL17-A and IL17-F, which suggest that CXCL1 might be an important player in neutrophilic allergic lung inflammation ([@b105-etm-0-0-8961]).

The contribution of CXCL2 and CXCL3 to mediating normal and asthmatic airway smooth muscle cell (ASMC) migration (through the ERK1/2 MAPK pathway) was demonstrated in a study that used human ASMCs isolated from lung transplant donors, which suggest a possible role in the pathogenesis of airway remodeling in asthma ([@b106-etm-0-0-8961]).

*CXCL8* (interleukin-8) is the primary cytokine involved in the recruitment of neutrophils to the site of damage or infection, representing one of the key mediators associated with inflammation. In some situations, IL-8-stimulated neutrophils could lead eosinophils to accumulate in the airways of asthma ([@b107-etm-0-0-8961]). IL-8 seems to contribute to the pathophysiology of allergic diseases through its roles in some aspects of these mechanisms. Serum IL-8 levels were higher in patients with asthma (non-allergic and allergic) compared with controls in a genetic study from Spain in adults ([@b108-etm-0-0-8961]) and in a pediatric population from Tunisia ([@b109-etm-0-0-8961]) due to the roles in neutrophil functions (release, chemotaxis, survival). Serum levels of IL-8 were significantly higher in patients with allergic asthma compared with allergic rhinitis and controls ([@b110-etm-0-0-8961]), suggesting that IL-8 is associated with more severe inflammatory response. In addition, higher levels of IL-8 were found in BALF of asthmatic patients compared with healthy controls, the authors proposed that IL-8 might augment eosinophil trans-basement membrane migration by releasing superoxide anion, matrix metalloproteinase, leukotriene B4, and platelet-activating factor ([@b111-etm-0-0-8961]). Elevated concentrations of IL-8 were found in patients with AR/chronic sino-sinusitis and concomitant nasal polyps ([@b112-etm-0-0-8961],[@b113-etm-0-0-8961]). IL-8 levels were higher in nasal biopsy specimens from patients with persistent AR vs. controls ([@b114-etm-0-0-8961]). Pelikan demonstrated high concentrations of IL-8 in tears from patients with AR after nasal provocation tests with allergen ([@b115-etm-0-0-8961],[@b116-etm-0-0-8961]). In conclusion, IL-8 is a key player in the pathogenesis of asthma through its roles in neutrophil functions.

Moreover, it was shown that not only is allergic sensitization related to elevated levels of IL-8, but it is also related to pollution. For instance, it was found that diesel exhaust particles (DEP) induce expression of IL-8 in nasal fibroblasts ([@b117-etm-0-0-8961]) and in primary nasal epithelial cells (NECs) ([@b118-etm-0-0-8961]), suggesting that air pollution might induce or aggravate allergic rhinitis through this chemokine ([@b117-etm-0-0-8961]).

### Chemokines associated with other types of lymphocytes. Th9 lymphocytes

CCL4 was significantly associated with a mix of lymphocytes (Th1, Th2, Th9, Th17) in subjects with severe asthma ([@b119-etm-0-0-8961]).

T~FH~ *lymphocytes.* The plasma levels of CXCL13 were significantly elevated and correlated with a subset of T~FH~ cells: T~FH2~ in patients with atopic asthma ([@b120-etm-0-0-8961]).

*iNKT lymphocytes.* A number of studies connected β and δ families of chemokines with these lymphocytes. NKT cells previously treated with CCL2 in contact with naïve T cells determined them to produce IL-4 in a murine study ([@b121-etm-0-0-8961]). Another murine study demonstrated that the stimulation of NKT cells with a specific ligand-α-galactosylceramide enhanced ragweed-induced IL-4 and CCL11 production ([@b122-etm-0-0-8961]). The duet CCR2/CCL2 was reduced in control mice vs. OVA-sensitized mice in a study that evaluated the expression of CD1d, an MHC-1 like molecule, responsible for presenting glycolipids to iTCR and iNKT cells conducting exacerbate airway inflammation and up-regulating IgE production ([@b123-etm-0-0-8961]). Along with other proteins, CXCL15 contributed to iNKT regulated AHR via altering leukocyte chemotaxis in a murine study ([@b124-etm-0-0-8961]). Data from animal studies (murine) demonstrate that iNKT cell-mediated XCL1-XCR1 axis promotes AHR by recruiting CD103^+^ DCs into the lung in patients with allergic asthma ([@b125-etm-0-0-8961]).

6. Conclusions
==============

Interleukins were used in the last two decades in order to define and characterize the classical Th2/non-Th2 endotype, as well as the newest Th2/Th17. As shown, CCs appear to be good candidates for a comprehensive characterization of endotypes.
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